secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-08-27T21:24:44+00:00
Accession:  0001140361-26-034735
Event type: regulatory
Sentiment:  positive
Materiality: 1.00
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Roivant's LISRAYA (brepocitinib) for dermatomyositis; now available in U.S.
--------------------------------------------------------------------------------

- FDA approved LISRAYA (brepocitinib) 30 mg once-daily for adults with dermatomyositis; first targeted therapy approved for DM.
- In Phase 3 VALOR trial, 55% on LISRAYA achieved moderate/better improvement plus minimal/no steroid use vs 30% on placebo at 52 weeks.
- 62% on LISRAYA tapered to minimal/no steroids vs 38% on placebo; 45% came off steroids entirely vs 29% on placebo.
- LISRAYA is available immediately in U.S.; eligible patients may pay as little as $0/month via My Compass Support program.
- Investor call scheduled for August 28, 2026 at 8:00 a.m. ET to discuss the approval and pipeline updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/0001140361-26-034735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-034735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer